# Intercept Pharmaceuticals Inc. (ICPT) Source: https://www.quantisnow.com/company/ICPT Generated: 2026-11-14T12:11:34.715Z - Ticker: ICPT - Exchange: NASDAQ - Sector: Health Care - Industry: Biotechnology: Pharmaceutical Preparations - IPO year: 2012 - Website: interceptpharma.com ## About Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York. ## Latest ICPT news and filings - 2024-05-09 12:00 UTC [Conference Announcement] [Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference](https://www.quantisnow.com/insight/intercept-announces-new-pbc-data-analyses-to-be-presented-at-5475344) - 2024-02-29 13:30 UTC [Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC](https://www.quantisnow.com/insight/intercept-announces-fda-acceptance-of-supplemental-new-drug-application-for-5303934) - 2024-02-13 19:05 UTC [Market Insight] [CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst](https://www.quantisnow.com/insight/cymabay-therapeutics-deal-may-not-be-needle-moving-for-100b-5253958) - 2023-11-20 17:09 UTC [SEC Form 15-12G filed by Intercept Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-intercept-pharmaceuticals-inc-5095508) - 2023-11-15 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Intercept Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-intercept-pharmaceuticals-inc-5086050) - 2023-11-15 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Intercept Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-intercept-pharmaceuticals-inc-5085843) - 2023-11-15 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Intercept Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-intercept-pharmaceuticals-inc-5085804) - 2023-11-13 19:51 UTC [SEC Form 4] [Akkaraju Srinivas returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/akkaraju-srinivas-returned-154109-worth-of-shares-to-the-company-5080349) - 2023-11-13 19:47 UTC [SEC Form 4] [Fundaro Paolo returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/fundaro-paolo-returned-154109-worth-of-shares-to-the-company-5080346) - 2023-11-13 19:49 UTC [SEC Form 4] [Venezia Rocco returned $278,711 worth of shares to the company (14,669 units at $19.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/venezia-rocco-returned-278711-worth-of-shares-to-the-company-5080345) - 2023-11-13 19:49 UTC [SEC Form 4] [Berrey M Michelle returned $984,010 worth of shares to the company (51,790 units at $19.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/berrey-m-michelle-returned-984010-worth-of-shares-to-the-5080343) - 2023-11-13 19:46 UTC [SEC Form 4] [Richardson Linda M returned $505,115 worth of shares to the company (26,585 units at $19.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/richardson-linda-m-returned-505115-worth-of-shares-to-the-5080341) - 2023-11-13 19:46 UTC [SEC Form 4] [Benatti Luca returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/benatti-luca-returned-154109-worth-of-shares-to-the-company-5080340) - 2023-11-13 19:45 UTC [SEC Form 4] [Sblendorio Glenn returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/sblendorio-glenn-returned-154109-worth-of-shares-to-the-company-5080339) - 2023-11-13 19:44 UTC [SEC Form 4] [Miller-Rich Nancy returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/miller-rich-nancy-returned-154109-worth-of-shares-to-the-company-5080335) - 2023-11-13 19:44 UTC [SEC Form 4] [Santini Gino returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/santini-gino-returned-154109-worth-of-shares-to-the-company-5080331) - 2023-11-13 19:43 UTC [SEC Form 4] [Rosa-Bjorkeson Dagmar returned $220,875 worth of shares to the company (11,625 units at $19.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/rosa-bjorkeson-dagmar-returned-220875-worth-of-shares-to-the-company-5080329) - 2023-11-13 19:43 UTC [SEC Form 4] [Gottesdiener Keith Michael returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/gottesdiener-keith-michael-returned-154109-worth-of-shares-to-the-5080327) - 2023-11-13 19:42 UTC [SEC Form 4] [Ford David A returned $406,600 worth of shares to the company (21,400 units at $19.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/ford-david-a-returned-406600-worth-of-shares-to-the-5080325) - 2023-11-13 19:42 UTC [SEC Form 4] [Freedberg Jared returned $641,478 worth of shares to the company (33,762 units at $19.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/freedberg-jared-returned-641478-worth-of-shares-to-the-company-5080324) - 2023-11-13 19:41 UTC [SEC Form 4] [Bradbury Daniel returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/bradbury-daniel-returned-154109-worth-of-shares-to-the-company-5080321) - 2023-11-13 19:40 UTC [SEC Form 4] [Durso Jerome Benedict returned $1,953,675 worth of shares to the company (102,825 units at $19.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/durso-jerome-benedict-returned-1953675-worth-of-shares-to-the-5080318) - 2023-11-13 19:40 UTC [SEC Form 4] [Pruzanski Mark closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/pruzanski-mark-closing-all-direct-ownership-in-the-company-sec-5080317) - 2023-11-13 19:40 UTC [SEC Form 4] [Saik Andrew returned $859,636 worth of shares to the company (45,244 units at $19.00), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/saik-andrew-returned-859636-worth-of-shares-to-the-company-5080316) - 2023-11-13 13:33 UTC [Market Chatter] [Intercept Announces New Phase 2 Data Showing Significant Impact Of OCA-Bezafibrate Combination On Normalization Of Multiple Key Biomarkers Of PBC-Induced Liver Damage At AASLD The Liver Meeting 2023](https://www.quantisnow.com/insight/intercept-announces-new-phase-2-data-showing-significant-impact-of-5079033) - 2023-11-10 13:02 UTC [Market Chatter] [Intercept Announces New Findings From Long-term Extension Of Landmark POISE Trial In PBC Showing Importance Of Biomarkers Beyond ALP At AASLD The Liver Meeting 2023](https://www.quantisnow.com/insight/intercept-announces-new-findings-from-long-term-extension-of-landmark-poise-5077015) - 2023-11-08 21:44 UTC [SEC Form 8-K] [Intercept Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Events That Accelerate or Increase a Direct Financial Obligation, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/intercept-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-5071130) - 2023-11-08 21:28 UTC [SEC Form POS AM filed by Intercept Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-intercept-pharmaceuticals-inc-5070857) - 2023-11-08 21:28 UTC [SEC Form POS AM filed by Intercept Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-intercept-pharmaceuticals-inc-5070842) - 2023-11-08 21:26 UTC [SEC Form POS AM filed by Intercept Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-intercept-pharmaceuticals-inc-5070815) - 2023-11-08 21:21 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Intercept Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-intercept-pharmaceuticals-inc-5070729) - 2023-11-08 21:21 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Intercept Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-intercept-pharmaceuticals-inc-5070719) - 2023-11-08 21:20 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Intercept Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-intercept-pharmaceuticals-inc-5070706) - 2023-11-08 21:19 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Intercept Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-intercept-pharmaceuticals-inc-5070683) - 2023-11-08 21:18 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Intercept Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-intercept-pharmaceuticals-inc-5070663) - 2023-11-08 21:17 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Intercept Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-intercept-pharmaceuticals-inc-5070650) - 2023-11-08 21:17 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Intercept Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-intercept-pharmaceuticals-inc-5070641) - 2023-11-08 21:15 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Intercept Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-intercept-pharmaceuticals-inc-5070588) - 2023-11-08 21:13 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Intercept Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-intercept-pharmaceuticals-inc-5070450) - 2023-11-08 14:13 UTC [Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.](https://www.quantisnow.com/insight/alfasigma-completes-acquisition-of-intercept-pharmaceuticals-inc-5068957) ## More - Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ICPT - Earnings history: https://www.quantisnow.com/earnings/ICPT - Dividend history: https://www.quantisnow.com/dividends/ICPT - Insider transactions: https://www.quantisnow.com/insiders/ICPT - Options chain: https://www.quantisnow.com/options/ICPT - SEC 8-K filings only: https://www.quantisnow.com/company/ICPT/8-k - RSS and alerts for ICPT: https://www.quantisnow.com/docs/rss-feeds.md